Literature DB >> 15954103

Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome.

Mato Nagel1, Sylvia Nagorka, Oliver Gross.   

Abstract

This study summarizes 47 novel mutations identified during routine molecular diagnostics for Alport syndrome. We detected 34 in COL4A5, the gene responsible for X-linked Alport syndrome, and 13 in COL4A3 and COL4A4, the genes responsible for autosomal recessive Alport syndrome. A high detection rate of 90% was achieved among patients with typical clinical symptoms and a characteristic family history in both X-linked and autosomal recessive forms, and it can be assumed that most relevant mutations have been identified. In numerous positively tested patients, genetic variations which are unknown were detected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15954103     DOI: 10.1002/humu.9349

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  20 in total

1.  Improving mutation screening in familial hematuric nephropathies through next generation sequencing.

Authors:  Vincent Morinière; Karin Dahan; Pascale Hilbert; Marieline Lison; Said Lebbah; Alexandra Topa; Christine Bole-Feysot; Solenn Pruvost; Patrick Nitschke; Emmanuelle Plaisier; Bertrand Knebelmann; Marie-Alice Macher; Laure-Hélène Noel; Marie-Claire Gubler; Corinne Antignac; Laurence Heidet
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

2.  A novel COL4A3 mutation causes autosomal-recessive Alport syndrome in a large Turkish family.

Authors:  Asli Subasioglu Uzak; Bulent Tokgoz; Munis Dundar; Mustafa Tekin
Journal:  Genet Test Mol Biomarkers       Date:  2013-01-08

3.  Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome.

Authors:  Fangrui Ding; Larysa Wickman; Su Q Wang; Yanqin Zhang; Fang Wang; Farsad Afshinnia; Jeffrey Hodgin; Jie Ding; Roger C Wiggins
Journal:  Kidney Int       Date:  2017-07-26       Impact factor: 10.612

4.  COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome.

Authors:  Helen Storey; Judy Savige; Vanessa Sivakumar; Stephen Abbs; Frances A Flinter
Journal:  J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 10.121

5.  Renal, auricular, and ocular outcomes of Alport syndrome and their current management.

Authors:  Yanqin Zhang; Jie Ding
Journal:  Pediatr Nephrol       Date:  2017-09-01       Impact factor: 3.714

Review 6.  The triple helix of collagens - an ancient protein structure that enabled animal multicellularity and tissue evolution.

Authors:  Aaron L Fidler; Sergei P Boudko; Antonis Rokas; Billy G Hudson
Journal:  J Cell Sci       Date:  2018-04-09       Impact factor: 5.285

7.  X-linked Alport syndrome caused by splicing mutations in COL4A5.

Authors:  Kandai Nozu; Igor Vorechovsky; Hiroshi Kaito; Xue Jun Fu; Koichi Nakanishi; Yuya Hashimura; Fusako Hashimoto; Koichi Kamei; Shuichi Ito; Yoshitsugu Kaku; Toshiyuki Imasawa; Katsumi Ushijima; Junya Shimizu; Yoshio Makita; Takao Konomoto; Norishige Yoshikawa; Kazumoto Iijima
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-02       Impact factor: 8.237

Review 8.  Alport syndrome--insights from basic and clinical research.

Authors:  Jenny Kruegel; Diana Rubel; Oliver Gross
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

9.  Identification of a novel COL4A5 mutation in a Chinese family with X-linked Alport syndrome using exome sequencing.

Authors:  Yi Guo; Jinzhong Yuan; Hui Liang; Jingjing Xiao; Hongbo Xu; Lamei Yuan; Kai Gao; Bin Wu; Yongchang Tang; Xiaorong Li; Hao Deng
Journal:  Mol Biol Rep       Date:  2014-02-13       Impact factor: 2.316

10.  Detection of large deletion mutations in the COL4A5 gene of female Alport syndrome patients.

Authors:  Kandai Nozu; Rafal Przybyslaw Krol; Yasufumi Ohtsuka; Koichi Nakanishi; Norishige Yoshikawa; Yoshimi Nozu; Hiroshi Kaito; Kyoko Kanda; Yuya Hashimura; Yuhei Hamasaki; Kazumoto Iijima; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2008-06-27       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.